Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Affiliations

• ¹ Montpellier University, Montpellier, France. [email protected].
• ² Rheumatology Department, Lapeyronie Hospital, Montpellier University, 34295, Montpellier Cedex 5, France. [email protected].
• ³ The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
• ⁴ NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK.
• ⁵ Griffith University of Queensland, Brisbane, Australia.
• ⁶ Charité University Hospital Berlin, Berlin, Germany.
• ⁷ Altoona Center for Clinical Research, Duncansville, PA, USA.
• ⁸ Gilead Sciences, Inc., Foster City, CA, USA.
• ⁹ Gilead Sciences K.K., Tokyo, Japan.
• ¹⁰ Galapagos NV, Mechelen, Belgium.
• ¹¹ Amsterdam Rheumatology and Clinical Immunology Center (amC) and Zuyderland MC, Heerlen, The Netherlands.
• ¹² Medical University of Vienna, Vienna, Austria.